GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (MIL:DIA) » Definitions » Cyclically Adjusted Price-to-FCF

Diasorin SpA (MIL:DIA) Cyclically Adjusted Price-to-FCF : 15.89 (As of Jun. 01, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA Cyclically Adjusted Price-to-FCF?

As of today (2025-06-01), Diasorin SpA's current share price is €91.36. Diasorin SpA's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €5.75. Diasorin SpA's Cyclically Adjusted Price-to-FCF for today is 15.89.

The historical rank and industry rank for Diasorin SpA's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MIL:DIA' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 15.69   Med: 39.23   Max: 80.8
Current: 15.89

During the past years, Diasorin SpA's highest Cyclically Adjusted Price-to-FCF was 80.80. The lowest was 15.69. And the median was 39.23.

MIL:DIA's Cyclically Adjusted Price-to-FCF is ranked better than
74.24% of 66 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.415 vs MIL:DIA: 15.89

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Diasorin SpA's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €1.317. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €5.75 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Diasorin SpA Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Diasorin SpA's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Cyclically Adjusted Price-to-FCF Chart

Diasorin SpA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.57 45.84 27.99 18.27 17.67

Diasorin SpA Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.19 17.39 18.91 17.67 15.91

Competitive Comparison of Diasorin SpA's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Diasorin SpA's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diasorin SpA's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Cyclically Adjusted Price-to-FCF falls into.


;
;

Diasorin SpA Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Diasorin SpA's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=91.36/5.75
=15.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Diasorin SpA's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.317/122.5000*122.5000
=1.317

Current CPI (Mar. 2025) = 122.5000.

Diasorin SpA Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.391 100.279 0.478
201509 0.737 100.000 0.903
201512 0.766 99.814 0.940
201603 0.615 99.600 0.756
201606 0.627 99.900 0.769
201609 0.904 100.100 1.106
201612 0.877 100.300 1.071
201703 0.935 101.000 1.134
201706 0.471 101.100 0.571
201709 0.893 101.200 1.081
201712 0.750 101.200 0.908
201803 0.679 101.800 0.817
201806 0.928 102.400 1.110
201809 0.823 102.600 0.983
201812 1.399 102.300 1.675
201903 0.878 102.800 1.046
201906 0.817 103.100 0.971
201909 1.495 102.900 1.780
201912 1.124 102.800 1.339
202003 1.018 102.900 1.212
202006 0.906 102.900 1.079
202009 0.906 102.300 1.085
202012 3.637 102.600 4.342
202103 1.859 103.700 2.196
202106 1.313 104.200 1.544
202109 2.327 104.900 2.717
202112 1.819 106.600 2.090
202203 2.456 110.400 2.725
202206 0.843 112.500 0.918
202209 2.359 114.200 2.530
202212 1.539 119.000 1.584
202303 0.766 118.800 0.790
202306 1.959 119.700 2.005
202309 1.501 120.300 1.528
202312 1.605 119.700 1.643
202403 1.405 120.200 1.432
202406 1.499 120.700 1.521
202409 2.457 121.200 2.483
202412 1.303 121.200 1.317
202503 1.317 122.500 1.317

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diasorin SpA  (MIL:DIA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Diasorin SpA Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).